These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 20537457)
21. Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group. Ariyoshi Y; Fukuoka M; Furuse K; Saijo N; Ikegami H; Nishiwaki Y; Tamura T; Shimoyama M; Suemasu K Jpn J Clin Oncol; 1994 Oct; 24(5):275-81. PubMed ID: 7967106 [TBL] [Abstract][Full Text] [Related]
25. Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy. Sodja E; Knez L; Kern I; Ovčariček T; Sadikov A; Cufer T Eur J Cancer; 2012 Dec; 48(18):3378-85. PubMed ID: 22795264 [TBL] [Abstract][Full Text] [Related]
26. Serum levels of pro-gastrin-releasing peptide for follow-up of patients with small cell lung cancer. Okusaka T; Eguchi K; Kasai T; Kurata T; Yamamoto N; Ohe Y; Tamura T; Shinkai T; Saijo N Clin Cancer Res; 1997 Jan; 3(1):123-7. PubMed ID: 9815547 [TBL] [Abstract][Full Text] [Related]
27. [Serial measurements of serum carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE) during chemotherapy of patients with inoperable lung cancer]. Fukuoka M; Takada M; Kamei T; Negoro S; Kusunoki Y; Matsui K; Ryu S; Sakai N; Takifuji N; Masuda N Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):871-80. PubMed ID: 3032108 [TBL] [Abstract][Full Text] [Related]
28. [Comparison of the degree of regression of small cell lung neoplasm in clinical-radiologic evaluation with levels of neuron specific enolase (NSE) in serum]. Rowińska-Zakrzewska E; Szturmowicz M; Sakowicz A; Pawlicka L; Remiszewki P; Szopiński J; Wiatr E; Zych J Pneumonol Alergol Pol; 1995; 63(11-12):601-8. PubMed ID: 8616474 [TBL] [Abstract][Full Text] [Related]
29. [Determination of various tumor markers, with special reference to neuron-specific enolase in lung cancer]. Yano H; Hino M; Nishiwaki Y; Kodama T; Hayashibe A; Kudo H; Inoue Y; Nishiyama Y; Sone Y; Oshima T Gan To Kagaku Ryoho; 1987 Jan; 14(1):77-83. PubMed ID: 3026257 [TBL] [Abstract][Full Text] [Related]
30. Dose-intensive therapy for extensive-stage small cell lung cancer and extrapulmonary small cell carcinoma: long-term outcome. Elias AD; Skarin AT; Richardson P; Ibrahim J; McCauley M; Frei E Biol Blood Marrow Transplant; 2002; 8(6):326-33. PubMed ID: 12108918 [TBL] [Abstract][Full Text] [Related]
31. Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Evans WK; Radwi A; Tomiak E; Logan DM; Martins H; Stewart DJ; Goss G; Maroun JA; Dahrouge S Am J Clin Oncol; 1995 Apr; 18(2):149-55. PubMed ID: 7534977 [TBL] [Abstract][Full Text] [Related]
32. High-dose ifosfamide, carboplatin and etoposide with autologous peripheral blood progenitor cell transplantation for small-cell lung cancer. Bessho A; Ueoka H; Kiura K; Tabata M; Sunami K; Katayama Y; Yamane H; Hiraki A; Harada M Anticancer Res; 1999; 19(1B):693-8. PubMed ID: 10216478 [TBL] [Abstract][Full Text] [Related]
33. [Neuron-specific enolase (NSE) in the surveillance of small cell cancers. An evaluation of the prognostic information using Markov's model]. Pujol JL; Boher JM; Grenier J; Quantin X; Saffont L; Daurès JP Rev Mal Respir; 1998 Sep; 15(4):519-25. PubMed ID: 9805763 [TBL] [Abstract][Full Text] [Related]
34. Doubling time of neuron-specific enolase and survival in small cell lung cancer patients. Results of a preliminary analysis. Splinter TA; Cooper EH; Oosterom R; Peake MD; Brown DA; Kho GS Eur J Respir Dis Suppl; 1987; 149():37-44. PubMed ID: 3034646 [TBL] [Abstract][Full Text] [Related]
35. [Serum NSE (neuron-specific enolase) levels in small cell lung cancer, with special reference to the measurement of serial serum NSE levels]. Kawachi S; Shimabukuro Z; Aoyama A; Yano T; Hasegawa K; Tsuboi E; Niitani H Gan To Kagaku Ryoho; 1987 Aug; 14(8):2469-74. PubMed ID: 3039919 [TBL] [Abstract][Full Text] [Related]
36. [Usefulness of monitoring levels of carcinoembryonic antigen, neuron-specific enolase and ferritin in serum of patients with small cell lung cancer for evaluating treatment outcome]. Szturmowicz M; Rogińska E; Roszkowski K; Kwiek S; Filipecki S; Rowińska-Zakrzewska E Pneumonol Alergol Pol; 1993; 61(9-10):489-95. PubMed ID: 8111325 [TBL] [Abstract][Full Text] [Related]
37. [Treatment monitoring of patients with small cell lung cancer by determining levels of serum neuron specific enolase]. Jassem E Pneumonol Alergol Pol; 1993; 61(1-2):56-60. PubMed ID: 8388760 [TBL] [Abstract][Full Text] [Related]
38. [Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival]. Załeska M; Szturmowicz M; Zych J; Roszkowska-Sliz B; Demkow U; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2010; 78(1):14-20. PubMed ID: 20162514 [TBL] [Abstract][Full Text] [Related]
39. Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer. Scagliotti GV; Piani M; Gatti E; Gozzelino F; Albera C; Pozzi E Eur Respir J; 1989 Sep; 2(8):746-50. PubMed ID: 2553476 [TBL] [Abstract][Full Text] [Related]
40. Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Pinson P; Joos G; Watripont P; Brusselle G; Pauwels R Respiration; 1997; 64(1):102-7. PubMed ID: 9044484 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]